Resumen
La enfermedad de Parkinson es la segunda enfermedad neurodegenerativa más prevalente en el mundo, y sus manifestaciones cardinales son la bradicinesia, el temblor y la rigidez. Aunque ha sido considerado un trastorno motor, actualmente se considera como un trastorno neurológico complejo que afecta diferentes sistemas, por lo que genera manifestaciones motoras y no motoras variadas, además de manifestaciones autonómicas sistémicas. Las manifestaciones cardiovasculares en pacientes con enfermedad de Parkinson son frecuentes y, además, provocan un gran impacto sobre la calidad de vida. A continuación, se realiza una revisión narrativa de las principales manifestaciones cardiovasculares de la enfermedad de Parkinson, y de sus mecanismos fisiopatológicos.
Citas
Hayes M. Parkinson's disease and parkinsonism. Am J Med. 2019; 132(7):802-7. DOI: 10.1016/j.amjmed.2019.03.001.
Palacios-Sánchez L, Torres M, Botero-Meneses J. James Parkinson and his essay on "shaking palsy", two hundred years later. Arq Neuropsiquiatr. 2017; 75(9):671-2. DOI: 10.1590/0004-282X20170108.
Todorova A, Jenner P, Ray Chaudhuri K. Non-motor Parkinson's: integral to motor Parkinson's, yet often neglected. Pract Neurol. 2014;14(5):310-22. doi: 10.1136/practneurol-2013-000741.
Merola A, Romagnolo A, Rosso M, Suri R, Berndt Z, Maule S, et al. Autonomic dysfunction in Parkinson's disease: a prospective cohort study. Mov Disord. 2018;33(3):391-397. doi: 10.1002/mds.27268.
Schapira A, Chaudhuri K, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017; 18(7):435-50. DOI: 10.1038/nrn.2017.62.
Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello T et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord. 2009; 24(11):1641-9. DOI: 10.1002/mds.22643.
Gulunay A, Cakmakli G, Yon M, Ulusoy E, Karakoc M. Frequency of non-motor symptoms and their impact on the quality of life in patients with Parkinson's disease: a prospective descriptive case series. Psychogeriatrics. 2020; 20(2):206-11. DOI: 10.1111/psyg.12489.
Prasuhn J, Piskol L, Vollstedt E, Graf J, Schmidt A, Tadic V et al. Non-motor symptoms and quality of life in subjects with mild parkinsonian signs. Acta Neurol Scand. 2017; 136(5):495-500. DOI: 10.1111/ane.12760.
Rodríguez-Violante M, Ospina-García N, Dávila-Avila N, Cruz-Fino D, Cruz-Landero A, Cervantes-Arriaga A. Motor and non-motor wearing-off and its impact in the quality of life of patients with Parkinson's disease. Arq Neuropsiquiatr. 2018; 76(8):517-21. DOI: 10.1590/0004-282X20180074.
Piqueras-Flores J, López-García A, Moreno-Reig A, González-Martínez A, Hernández-González A, Vaamonde-Gamo J et al. Structural and functional alterations of the heart in Parkinson's disease. Neurol Res. 2018; 40(1):53-61. DOI: 10.1080/01616412.2017.1390933.
Potashkin J, Huang X, Becker C, Chen H, Foltynie T, Marras C. Understanding the links between cardiovascular disease and Parkinson's disease. Mov Disord. 2020; 35(1):55-74. DOI: 10.1002/mds.27836.
Goldstein D, Holmes C, Li S, Bruce S, Metman L, Cannon R. Cardiac sympathetic denervation in Parkinson disease. Ann Intern Med. 2000; 133(5):338-47. DOI: 10.7326/0003-4819133-5-200009050-00009.
Goldstein D, Holmes C, Lopez G, Wu T, Sharabi Y. Cardiac sympathetic denervation predicts PD in at-risk individuals. Parkinsonism Relat Disord. 2018; 52:90-3. DOI: 10.1016/j.parkreldis.2017.10.003.
Coon E, Cutsforth-Gregory J, Benarroch E. Neuropathology of autonomic dysfunction in synucleinopathies. Mov Disord. 2018; 33(3):349-58. DOI: 10.1002/mds.27186.
Metzger J, Emborg M. Autonomic dysfunction in Parkinson disease and animal models. Clin Auton Res. 2019; 29(4):397-414. DOI: 10.1007/s10286-018-00584-7.
Mendoza-Velasquez J, Flores-Vazquez J, Barron-Velazquez E, Sosa-Ortiz AL, Illigens B, Siepmann T. Autonomic dysfunction in ?-synucleinopathies. Front Neurol. 2019; 10:363. DOI: 10.3389/fneur.2019.00363.
Mollenhauer B, Zimmermann J, SixeEDoring F, Focke N, Wicke T, Ebentheuer J et al. Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa). Mov Disord. 2019; 34(1):67-77. DOI: 10.1002/mds.27492.
Andican G, Konukoglu D, Bozluolcay M, Bayulkem K, Firtiina S, Burcak G. Plasma oxidative and inflammatory markers in patients with idiopathic Parkinson's disease. Acta Neurol Belg. 2012; 112(2):155-9. DOI: 10.1007/s13760-012-0015-3.
Huebecker M, Moloney E, Van der Spoel A, Priestman D, Isacson O, Hallett P et al. Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson's disease. Mol Neurodegener. 2019; 14(1):40. DOI: 10.1186/s13024-019-0339-z.
Taguchi Y, Liu J, Ruan J, Pacheco J, Zhang X, Abbasi J et al. Glucosylsphingosine promotes a-synuclein pathology in mutant GBA-associated Parkinson's disease. J Neurosci. 2017; 37(40):9617-31. DOI: 10.1523/JNEUROSCI.1525-17.2017.
Alcalay R, Mallett V, Vanderperre B, Tavassoly O, Dauvilliers Y, Wu R et al. SMPD1 mutations, activity, and a-synuclein accumulation in Parkinson's disease. Mov Disord. 2019; 34(4):526-35. DOI: 10.1002/mds.27642.
Guedes L, Chan R, Gomes M, Conceição V, Machado R, Soares T et al. Serum lipid alterations in GBA-associated Parkinson's disease. Parkinsonism Relat Disord. 2017; 44:58-65. DOI: 10.1016/j.parkreldis.2017.08.026.
Burbulla L, Song P, Mazzulli J, Zampese E, Wong Y, Jeon S et al. Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease. Science. 2017; 357(6357):1255-61. DOI: 10.1126/science.aam9080.
Rozani V, Gurevich T, Giladi N, El-Ad B, Tsamir J, Hemo B et al. Higher serum cholesterol and decreased Parkinson's disease risk: A statin-free cohort study. Mov Disord. 2018; 33(8):1298-305. DOI: 10.1002/mds.27413.
Huang X, Sterling N, Du G, Sun D, Stetter C, Kong L et al. Brain cholesterol metabolism and Parkinson's disease. Mov Disord. 2019; 34(3):386-95. DOI: 10.1002/mds.27609.
Sanjari H, Valitabar Z, Ashraf-Ganjouei A, Mojtahed M, Ghazi F, Hadi M. Cerebrospinal fluid C-reactive protein in Parkinson's disease: associations with motor and non-motor symptoms. NeuroMolecular Med. 2018; 20(3):376-85. DOI: 10.1007/s12017-018-8499-5.
Park J, Kim D, Park Y, Kwon D, Choi M, Jung J, Han K. Association of Parkinson disease with risk of cardiovascular disease and all-cause mortality: a nationwide, population-based cohort study. Circulation. 2020; 141(14):1205-7. DOI: 10.1161/CIRCULATIONAHA.119.044948.
Merola A, Romagnolo A, Rosso M, et al. Orthostatic hypotension in Parkinson's disease: does it matter if asymptomatic? Parkinsonism Relat Disord 2016;33:65-71.
Scorza F, Fiorini A, Scorza C, Finsterer J. Cardiac abnormalities in Parkinson's disease and Parkinsonism. J Clin Neurosci. 2018; 53:1-5. DOI: 10.1016/j.jocn.2018.04.031.
Fanciulli A, Campese N, Goebel G, Ndayisaba J, Eschlboeck S, Kaindlstorfer C et al. Association of transient orthostatic hypotension with falls and syncope in patients with Parkinson disease. Neurology. 2020; 95(21):e2854-65. DOI: 10.1212/WNL.0000000000010749.
Allcock L, Ullyart K, Kenny R, Burn D. Frequency of ortho-static hypotension in a community based cohort of patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2004; 75(10):1470-1. DOI: 10.1136/jnnp.2003.029413.
Goldstein D. Orthostatic hypotension as an early finding in Parkinson's disease. Clin Auton Res. 2006; 16(1):46-54. DOI: 10.1007/s10286-006-0317-8.
Goldstein D, Eldadah B, Holmes C, Pechnik S, Moak J, Saleem A et al. Neurocirculatory abnormalities in Parkinson disease with orthostatic hypotension: independence from levodopa treatment. Hypertension. 2005; 46(6):1333-9. DOI: 10.1161/01.HYP.0000188052.69549.e4.
Hiorth Y, Pedersen K, Dalen I, Tysnes O, Alves G. Ortho-static hypotension in Parkinson disease: a 7-year prospective population-based study. Neurology. 2019; 93(16):e1526-34. DOI: 10.1212/WNL.0000000000008314.
Li L, Guo P, Ding D, Lian T, Zuo L, Du F et al. Parkinson's disease with orthostatic hypotension: analyses of clinical characteristics and influencing factors. Neurol Res. 2019; 41(8):734-741. DOI: 10.1080/01616412.2019.1610224.
Arbogast S, Alshekhlee A, Hussain Z, McNeeley K, Chelimsky T. Hypotension unawareness in profound orthostatic hypotension. Am J Med. 2009; 122(6):574-80. DOI: 10.1016/j.amjmed.2008.10.040.
Strano S, Fanciulli A, Rizzo M, Marinelli P, Palange P, Tiple D et al. Cardiovascular dysfunction in untreated Parkinson's disease: A multi-modality assessment. J Neurol Sci. 2016; 370:251-5. DOI: 10.1016/j.jns.2016.09.036.
Longardner K, Bayram E, Litvan I. Orthostatic hypotension is associated with cognitive decline in Parkinson disease. Front Neurol. 2020;11:897. doi: 10.3389/fneur.2020.00897.
Pfeiffer R. Autonomic dysfunction in Parkinson's disease. Expert Rev Neurother. 2012; 12(6):697-706. DOI: 10.1586/ern.12.17.
Rueda M, Castro F. Disfunción autonómica en la enfermedad de Parkinson: enfoque práctico. Acta Neurol Colomb. 2019; 35(S1): 69-74. DOI: 10.22379/24224022252.
Suárez-Moro R, Castaño-García B. Trastornos cardiovasculares en la enfermedad de Parkinson. Rev Neurol. 2010; 50(S02):59. DOI: 10.33588/rn.50S02.2009741.
Umehara T, Nakahara A, Matsuno H, Toyoda C, Oka H. Predictors of postprandial hypotension in elderly patients with de novo Parkinson's disease. J Neural Transm. 2016; 123(11):1331-9. DOI: 10.1007/s00702-016-1594-6.
Km J, Lee S, Oh Y, Park J, An J, Park S, et al. Cardiovascular autonomic dysfunction in mild and advanced Parkinson's disease. J Mov Disord. 2016; 9(2):97-103. DOI: 10.14802/jmd.16001.
Mokwatsi G, Schutte A, Mels C, Kruger R. Morning blood pressure surge relates to autonomic neural activity in young non-dipping adults: The african-PREDICT study. Hear Lung Circ. 2018; 28(8):1197-205. DOI: 10.1016/j.hlc.2018.07.003.
Sommer S, Aral-Becher B, Jost W Nondipping in Parkinson's disease. Parkinsons Dis. 2011; 2011:897586. DOI: 10.4061/2011/897586.
Gibbons C, Schmidt P, Biaggioni I, Frazier-Mills C, Freeman R, Isaacson S, et al. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol. 2017; 264(8):1567-82. DOI: 10.1007/s00415-016-8375-x.
Fanciulli A, Góbel G, Ndayisaba J, Granata R, Duerr S, Strano S, et al. Supine hypertension in Parkinson's disease and multiple system atrophy. Clin Auton Res. 2016; 26(2):97-105. DOI: 10.1007/s10286-015-0336-4.
Umehara T, Matsuno H, Toyoda C, Oka H. Clinical characteristics of supine hypertension in de novo Parkinson disease. Clin Auton Res. 2016;26(1):15-21. DOI: 10.1007/s10286-015-0324-8.
Espay A, LeWitt P, Hauser R, Merola A, Masellis M, Lang A. Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisa-tion of treatment targets. Lancet Neurol. 2016 ;15(9):954-66. DOI: 10.1016/S1474-4422(16)30079-5.
Li K, Reichmann H, Ziemssen T. Recognition and treatment of autonomic disturbances in Parkinson's disease. Expert Rev Neurother. 2015; 15(10):1189-203. DOI: 10.1586/14737175.2015.1095093.
Baldacci F, Vergallo A, Del Dotto P, Ulivi M, Palombo C, Casolo G, et al. Occurrence of Takotsubo syndrome in a patient with Parkinson's disease after entacapone add-on. Parkinsonism Relat Disord. 2014; 20(11):1313-4. DOI: 10.1016/j.parkreldis.2014.09.009.
Lazaros G, Dimitriadis K, Xanthopoulou M, Latsios G, Antoniou C, Lazarou E, et al. Takotsubo cardiomyopathy and Parkinson's disease: an exceptionally uncommon clinical duet. Hellenic J Cardiol. 2019; 60(5):334-5. DOI: 10.1016/j.hjc.2018.12.002.
Santoro F, Carapelle E, Cieza S, Musaico F, Ferraretti A, D'Orsi G, et al. Potential links between neurological disease and Tako-Tsubo cardiomyopathy: a literature review. Int J Cardiol. 2013; 168(2):688-91. DOI: 10.1016/j.ijcard.2013.03.093.
De Pablo-Fernandez E, Tur C, Revesz T, Lees A, Holton J, Warner T. Association of autonomic dysfunction with disease progression and survival in Parkinson disease. JAMA Neurol. 2017; 74(8):970-6. DOI: 10.1001/jamaneurol.2017.1125.
Kim B, Lim Y, Lee H, Lee J, Kim K, Kim S, et al. Non-dipper pattern is a determinant of the inappropriateness of left ventricular mass in essential hypertensive patients. Korean Circ J. 2011; 41(4):191. DOI: 10.4070/kcj.2011.41.4.191.
Tsukamoto T, Kitano Y, Kuno S. Blood pressure fluctuation and hypertension in patients with Parkinson's disease. Brain Behav. 2013; 3(6):710-4. DOI: 10.1002/brb3.179.
Li Q, Wang C, Tang H, Chen S, Ma J. Stroke and coronary artery disease are associated with Parkinson's disease. Can J Neurol Sci. 2018; 45(5):559-65. DOI: 10.1017/cjn.2018.56.
Kitamura Y, Watanabe S, Taguchi M, Takagi K, Kawata T, Takahashi-Niki K, et al. Neuroprotective effect of a new DJ-1-binding compound against neurodegeneration in Parkinson's disease and stroke model rats. Mol Neurodegener. 2011; 6(1):48. DOI: 10.1186/1750-1326-6-48.
Dongworth R, Mukherjee U, Hall A, Astin R, Ong S-B, Yao Z, et al. DJ-1 protects against cell death following acute cardiac ischemia-reperfusion injury. Cell Death Dis. 2014; 5(2):e1082-e1082. DOI: 10.1038/cddis.2014.41.
Mochizuki H, Ebihara Y, Ugawa Y, Ishii N, Taniguchi A, Nagamachi S, et al. PR prolongation and cardiac 123I-MIBG uptake reduction in Parkinson's disease. Eur Neurol. 2015; 74(1-2):107-11. DOI: 10.1159/000439022.
Cunnington AL, Hood K, White L. Outcomes of screening Parkinson's patients for QTc prolongation. Parkinsonism Relat Disord. 2013; 19(11):1000-3. DOI: 10.1016/j.parkrel-dis.2013.07.001.
Charron P, Genest M, Richard P, Komajda M, Pochmalicki G. A familial form of conduction defect related to a mutation in the PRKAG2 gene. EP Eur. 2007; 9(8):597-600. DOI: 10.1093/europace/eum071.
Bacchi S, Chim I, Kramer P, Postuma R. Domperidone for hypotension in Parkinson's disease: A systematic review. J Parkinsons Dis. 2017; 7(4):603-17. DOI: 10.3233/JPD-171209.
Renoux C, Dell'Anello S, Khairy P, Marras C, Bugden S, Turin T, et al. Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease. Br J Clin Pharmacol. 2016; 82(2):461-72. DOI: 10.1111/bcp.12964.
Nishida N, Yoshida K, Hata Y Sudden unexpected death in early Parkinson's disease: neurogenic or cardiac death? Cardiovasc Pathol. 2017; 30:19-22. DOI: 10.1016/j.carpath.2017.06.001.
Scorza F, Cavalheiro E, Scorza C, Ferraz H. Sudden unexpected death in Parkinson's disease: Perspectives on what we have learned about sudden unexpected death in epilepsy (SUDEP). Epilepsy Behav. 2016; 57:124-5. DOI: 10.1016/j.yebeh.2016.01.035.
Scorza F, Carmo A, Fiorini A, Nejm M, Scorza C, Finsterer J, et al. Sudden unexpected death in Parkinson's disease (SUDPAR): a review of publications since the decade of the brain. Clinics. 2017; 72(11):649-51. DOI: 10.6061/clinics/2017(11)01.
Moscovich M, Boschetti G, Moro A, Teive H, Hassan A, Munhoz R. Death certificate data and causes of death in patients with parkinsonism. Parkinsonism Relat Disord. 2017; 41:99-103. DOI: 10.1016/j.parkreldis.2017.05.022.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.